Delta4 At PICKED
Teaming Up for Better CKD Care: Delta4 at the PICKED & DisCo-I Meeting in Toulouse | May 13-15, 2025 From May 13–15, 2025, Delta4’s Computational Biology Lead, Paul Perco, and Enrico Bono, MSCA-PICKED PhD Student, joined a dynamic mix of researchers, clinicians, and MSCA fellows in sunny Toulouse for a joint meeting of the PICKED […]
Delta4 Leads Training on Big Data Applications in CKD Research at PerMediK Lisbon, March 2025
Continuing its active engagement with the COST Action PerMediK network, Delta4 participated in the 6th Management Committee Meeting and Action Workshop held in Lisbon, Portugal on March 14–15, 2025. Representing Delta4, Lead Software Engineer Matthias Ley led the opening training session titled “Leveraging Big Data for Chronic Kidney Disease Research: Real-World Use-Cases and Data Skills […]
Delta4 Secures European Patents for Two Compounds as Candidate Treatments for Focal Segmental Glomerulosclerosis (FSGS)
Vienna, Austria – January 31th, 2025 – Delta4, a leader in AI-driven drug discovery and indication expansion, is proud to announce that it has been granted European patents for two innovative compounds positioned as candidate treatments for focal segmental glomerulosclerosis (FSGS), a rare and serious kidney disease. These patents mark a significant milestone in Delta4’s […]
Delta4 Announces Prof. Doron Lancet To Join Scientific Advisory Board
VIENNA, Austria, March 6th, 2023 — Delta4, a digital drug discovery company focusing on the identification of new indications for existing drug compounds, today announced that Prof. Doron Lancet will join its Scientific Advisory Board. Prof. Lancet is a distinguished scientist in the area of genetics and systems biology. “We are excited to have Prof. […]
4P-Pharma And Delta4 Join Forces To Find And Develop Treatments For A Rare Autoimmune Chronic Liver Disease
Paris (France) and Vienna (Austria), 31st May 2022 – 4P-Pharma, a French clinical-stage biotechnology company, and Delta4, an Austrian digital drug development company, today announce the signing of a collaboration agreement. Under the agreement, both companies will jointly identify and develop first-in-class drug candidates for a rare autoimmune chronic liver disease for which currently no […]
Delta4, in preparation for the first clinical study, focused on FSGS
Focal Segmental Glomerulosclerosis (FSGS) is a devastating clinical condition with defined glomerular histopathology and yet a multifaceted pathophysiological, histological, and genetic background. FSGS patients often progress to end-stage renal disease requiring dialysis and/or kidney transplantation, adding a significant socioeconomic burden to the individual burden of patients. There are approximately 140.000 patients with FSGS worldwide, qualifying […]
Delta4 Announces Dr. Hans Lehrach to Join Scientific Advisory Board
VIENNA, Austria, September 27th, 2021 — Delta4, a digital drug discovery company focusing on the identification of new indications for existing drug compounds, today announced that Dr. Hans Lehrach will join its Scientific Advisory Board. Prof. Lehrach is a distinguished scientist in the area of genomics. „We are excited to have Dr. Lehrach join our […]
Press Release – April ’21
Delta4 Announces Closing of Multi-million Series A Financing Round Company to Expand Focus Beyond Renal Diseases and COVID-19 Compounds Identified in Current Discovery Programs Ready for Clinical Development Vienna, Europe (April 7, 2021) – Delta4, a digital drug discovery company focusing on the identification of new indications for existing drug compounds, today announced that it […]
Press Release – June 2020
Delta4 Announces Results Achieved with Drug Discovery Platform Vienna, Europe (June 2, 2020) – Delta4, a biotech company using its proven digital drug discovery platform to identify new indications for approved drugs, today announced recent results achieved in two drug discovery and development programs. In its lead program, which aims at developing a therapy for […]